Get the Stockscreener App
3.25
6.21%
0.19
After Hours:
3.29
0.04
+1.23%
Nautilus Biotechnology Inc stock is traded at $3.25, with a volume of 275.59K.
It is up +6.21% in the last 24 hours and up +39.48% over the past month.
Nautilus Biotechnology Inc is a development stage life sciences company creating a platform technology for quantifying and unlocking the complexity of the human proteome. The Company transform the field of proteomics by democratizing access to the proteome and enabling fundamental advancements across human health and medicine. Its products includes: Proteome Analysis System, Reagent Kits, Software and analysis.
See More
Previous Close:
$3.06
Open:
$3.03
24h Volume:
275.59K
Relative Volume:
0.98
Market Cap:
$411.33M
Revenue:
-
Net Income/Loss:
$-59.00M
P/E Ratio:
-6.9548
EPS:
-0.4673
Net Cash Flow:
$-51.97M
1W Performance:
+3.83%
1M Performance:
+39.48%
6M Performance:
+195.45%
1Y Performance:
+322.02%
1-Day Range:
$3.03
$3.275
1-Week Range:
$2.83
$3.275
52-Week Range:
$0.62
$4.3101
Nautilus Biotechnology Inc Stock (NAUT) Company Profile
Name
Nautilus Biotechnology Inc
Sector
Industry
Phone
206-333-2001
Address
2701 EASTLAKE AVE EAST, SEATTLE
Compare NAUT vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NAUT
Nautilus Biotechnology Inc
|
3.25 | 387.29M | 0 | -59.00M | -51.97M | -0.4673 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Nautilus Biotechnology Inc Stock (NAUT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-05-24 | Downgrade | Goldman | Neutral → Sell |
| Jun-27-24 | Initiated | Guggenheim | Buy |
| Jun-03-24 | Resumed | Jefferies | Hold |
| Jan-06-22 | Initiated | Morgan Stanley | Equal-Weight |
| Nov-02-21 | Initiated | Cowen | Outperform |
| Aug-04-21 | Initiated | Goldman | Neutral |
| Jul-13-21 | Initiated | Jefferies | Buy |
View All
Nautilus Biotechnology Inc Stock (NAUT) Latest News
Nautilus Biotechnology (NAUT) price target increased by 60.00% to 4.08 - MSN
Here is why Nautilus Biotechnology (NAUT) is one of the best life sciences penny stocks to buy - MSN
Here is Why Nautilus Biotechnology (NAUT) is One of the Best Life Sciences Penny Stocks to Buy - Insider Monkey
How does Nautilus Biotechnology Inc compare to its peersProduct Launch & AI Powered Buy/Sell Recommendations - baoquankhu1.vn
Published on: 2026-04-11 15:42:56 - baoquankhu1.vn
Nautilus Biotechnology to Announce First Quarter 2026 Financial Results on April 28, 2026 - Investing News Network
NAUT PE Ratio & Valuation, Is NAUT Overvalued - Intellectia AI
NAUT Technical Analysis & Stock Price Forecast - Intellectia AI
Published on: 2026-03-31 08:20:41 - baoquankhu1.vn
Nautilus Biotechnology And 2 Other Compelling Penny Stocks For Your Watchlist - Sahm
Nautilus Biotechnology accelerates with Voyager Platform launch and first customer announcements - Traders Union
Nautilus Biotechnology at Investor Summit: Innovative Proteomics Pathway By Investing.com - Investing.com India
Nautilus Biotechnology Unveils Voyager Proteomics Platform, Targets Beta Access in 2H and Launch Next Year - marketbeat.com
Nautilus Biotechnology (NASDAQ:NAUT) Sets New 52-Week HighWhat's Next? - MarketBeat
Aug Chart Watch: Is Nautilus Biotechnology Inc forming a breakout patternTrade Entry Report & Consistent Profit Focused Trading Strategies - baoquankhu1.vn
Nautilus Biotechnology to Participate in the Investor Summit Group Virtual Conference - bitget.com
Nautilus management presents online March 25; webcast stays available - Stock Titan
Technical Analysis: Is Nautilus Biotechnology Inc stock a smart retirement pick2026 Earnings & Comprehensive Market Scan Insights - baoquankhu1.vn
If You Invested $1,000 in Nautilus Biotechnology Inc (NAUT) - Stock Titan
Published on: 2026-03-21 20:59:37 - baoquankhu1.vn
Baylor College of Medicine initiates research with Nautilus Biotechnology Voyager Platform - Traders Union
Nautilus Biotechnology Announces Baylor College of Medicine as First Early Access Program Customer for Voyager Platform - Bitget
Nautilus Biotechnology Announces Baylor College of Medicine as First Early Access Program ... - Bluefield Daily Telegraph
Nautilus Biotechnology Announces Baylor College of Medicine - GlobeNewswire
What’s the MACD signal for Nautilus Biotechnology Inc.July 2025 Chart Watch & High Win Rate Trade Tips - mfd.ru
Aug Sectors: Is Nautilus Biotechnology Inc forming a breakout patternWeekly Investment Summary & Daily Chart Pattern Signals - baoquankhu1.vn
Nautilus names Amber Faust VP of sales - The Pharma Letter
Sujal Patel Buys 25,000 Shares of Nautilus Biotechnology (NASDAQ:NAUT) Stock - MarketBeat
[Form 4] Nautilus Biotechnology, Inc. Insider Trading Activity - Stock Titan
Executive Parag Mallick receives 280,000 stock options at Nautilus (NAUT) - Stock Titan
Nautilus (NAUT) CEO Sujal Patel receives 650,000 stock option award - Stock Titan
Nautilus Biotechnology (NAUT) Chief People Officer granted 160,000 options - Stock Titan
Nautilus (NAUT) General Counsel receives 160,000-share stock option grant - Stock Titan
Nautilus Biotechnology appoints Amber Faust as VP of sales By Investing.com - Investing.com Canada
Nautilus Biotechnology names Amber Faust as Vice President of Sales to drive proteomics expansion - Traders Union
NAUT: New proteomics platform promises comprehensive, reproducible protein analysis with broad applications - TradingView
Nautilus Biotechnology Appoints Proteomics Commercial Leader Amber Faust as Vice President of Sales - BioSpace
Nautilus Biotechnology appoints proteomics commercial leader Amber Faust as vice president of sales - marketscreener.com
Nautilus Biotechnology appoints Amber Faust as VP of sales - Investing.com
Sales veteran joins Nautilus to push single-molecule proteomics into labs - Stock Titan
Guggenheim Forecasts Strong Price Appreciation for Nautilus Biotechnology (NASDAQ:NAUT) Stock - Defense World
Aug Big Picture: What are PROFs growth levers2025 EndofYear Setup & Free High Accuracy Swing Entry Alerts - baoquankhu1.vn
NAUT Should I Buy - Intellectia AI
Nautilus Biotechnology (NAUT) Target Price Raised by Guggenheim - GuruFocus
Nautilus debuts Voyager platform in push toward next-gen proteomics - Longevity.Technology
Nautilus Biotechnology (NASDAQ:NAUT) Price Target Raised to $4.00 at Guggenheim - MarketBeat
Nautilus Biotechnology, Inc. (NASDAQ:NAUT) Q4 2025 Earnings Call Transcript - Insider Monkey
Nautilus Biotechnology stock price target raised to $4 by Guggenheim - Investing.com Canada
Nautilus (NAUT) Q4 2025 Earnings Call Transcript - The Globe and Mail
Nautilus Biotechnology, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Nautilus Biotechnology Q4 Earnings Call Highlights - MarketBeat
Nautilus Biotechnology Inc Stock (NAUT) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.69%
0.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):